Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes?
BACKGROUND
Studies investigating genetic risk factors for susceptibility to rheumatoid arthritis (RA) studied anti-citrullinated peptide antibody (CCP)-positive RA more frequently than anti-CCP-negative RA. One of the reasons for this is the perception that anti-CCP-negative RA may include patients that fulfilled criteria for RA but belong to a wide range of diagnoses. We aimed to evaluate the validity of this notion and explored whether clinical subphenotypes can be discerned within anti-CCP-negative RA.


METHODS
The 318 patients with anti-CCP-negative RA (1987 ACR criteria), included in the Leiden Early Arthritis Clinic between 1993 and 2006, were studied for baseline characteristics and radiologic progression data during a mean follow-up of 5 years. Grouping was studied both at variable and patient levels. Principal components analysis and partial least-squares regression were applied to study for clustering of variables. A cluster analysis was performed to look for clustering of patients.


RESULTS
The simultaneous presence of patient characteristics at disease presentation was observed for several groups; however, the three largest groups of patients' characteristics explained only 26.5% of the total variance. Plotting the contribution of each patient to these three groups did not reveal clustering of patients. Comparable observations were made when data on progression of joint destruction were studied in relation to baseline clinical data. A cluster analysis, evaluating whether patients resemble each other, revealed no grouping of patients. Altogether, no clinically distinguishable subphenotypes were observed.


CONCLUSIONS
The current data provide evidence that, for risk-factor studies, anti-CCP-negative RA patients can be studied as one group.
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. d.p.c.de_rooy@lumc.nl
Diederik P C
DP
De Rooy
Annemiek
A
Willemze
Bart
B
Mertens
Tom W J
TW
Huizinga
Annette H M
AH
Van der Helm-van Mil
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000175:diagnosis* / Q000276:immunology*; D001323:Autoantibodies / Q000096:biosynthesis / Q000097:blood*; D015331:Cohort Studies; D019317:Evidence-Based Medicine / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016130:Immunophenotyping / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology*; D011159:Population Surveillance / Q000379:methods; D012307:Risk Factors
D001323:Autoantibodies; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide